UBS analyst Ashwani Verma upgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Neutral to Buy with a price target of $307.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Upgrades